CoChat

Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma

Kähler, Katharina C., Hauschild, Axel · 2011 · JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Cited by 108

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Summary: Immune‐modifying monoclonal antibodies may induce or enhance the natural immune response against tumor cells. The complex interaction between antigen‐presenting cells and T lymphocytes as an immune response is strongly affected by anti‐CD152 (CTLA‐4)‐antibodies. The cytotoxic T‐lymphocyte (CTLA‐4) receptor binds molecules of the B7‐family which leads to a suppression of T cells. Specific CTLA‐4 antibodies induce an unrestrained T‐cell activation. Treatment with the CTLA‐4 antibodies ipilimumab and tremelimumab has been investigated in metastatic melanoma only within clinical trials. Currently, the critical phase III trial on ipilimumab is in the final analysis process and expected to lead to approval. CTLA‐4 antibodies belong to the most promising new molecules for the treatment of advanced melanoma. During treatment with CTLA‐4 antibodies, distinct adverse events may occur. Treating physicians must be familiar with their appropriate treatment and prophylaxis. The most frequently observed side effects are diseases such as an autoimmune colitis which is typically characterized by a mild to moderate, but occasionally also severe and persistent diarrhea. Other autoimmune‐mediated side effects like hypophysitis, hepatitis, iridocyclitis or an exacerbation of lupus nephritis have been reported in the literature. Their early recognition and treatment are mandatory to reduce the risk of sequelae for CTLA‐4‐antibod‐treated patients. Autoimmune‐mediated side effects are reported to correlate positively with treatment response. We review the mechanisms of action, provide an update on clinical trials with the two CTLA‐4‐antibodies for metastatic melanoma, and present detailed recommendations for managing the side effects of these new agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1610-0387.2010.07568.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 108

Metadata

Authors
Kähler, K. C., & Hauschild, A.
Venue
JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Publisher
Wiley
Published
2010-11-17
Volume
9
Issue
4
Pages
277-286
ISSN
  • 1610-0379 (ISSN-L)
  • 1610-0387
OpenAlex
W1529517822
Cited by
108
References
7
FWCI
4.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma. https://app.cochat.ai/papers/10.1111/j.1610-0387.2010.07568.x
The paper
Kähler, K. C., & Hauschild, A. (2011). Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/j.1610-0387.2010.07568.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.